

REMARKS

Applicants elect with traverse Group III, claims 7, 8 and 11-13, drawn to the use of a DNA sequence encoding a plant dihydroorotase to identify inhibitors.

The examiner stated that the inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. The examiner states various reasons why the groups lack the same or corresponding features. The examiner does not, however, provide a reason as to why Groups I and III are separable.

Applicants believe that, at least, Groups I and III form a single general inventive concept. The special technical feature is the inventive DNA sequence. It represents an advance over the prior art.

Also, since there can be more than one special feature, applicants believe groups I-V all form a single general inventive concept. The common feature is dihydroorotase inhibitor. This is present in all groups.

Reconsideration of the examiner's position is therefore requested.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF

A handwritten signature in black ink, appearing to read "Daniel Kim", written in a cursive style.

Daniel S. Kim

Reg. No. 51877

1350 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100
DSK/sb